Holly Young Reese, NP
Family · Fort Wayne, INNPI 1194164863
Payments from drug & device makers
Across 49 payments — averaging $182.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Insulet Corporation$670
- Bayer$381
- Inspire Medical Systems, Inc.$357
- Abbott$287
- Tactile Systems Technology Inc$168
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$5,36060%
- Travel & lodging$2293%
- Food & beverage$3,31237%
- Other$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $5,636 |
| Insulet Corporation | 11 | $670 |
| Bayer | 3 | $381 |
| Inspire Medical Systems, Inc. | 3 | $357 |
| Abbott | 4 | $287 |
| Tactile Systems Technology Inc | 7 | $168 |
| Bioventus LLC | 1 | $132 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Lilly USA, LLC | 1 | $122 |
| Insmed, Inc. | 1 | $118 |
| Biogen | 1 | $113 |
| Gilead | 1 | $109 |
| Corcept Therapeutics | 1 | $104 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $97 |
| Lundbeck LLC | 1 | $97 |
| Boston Scientific | 1 | $95 |
| AstraZeneca | 1 | $94 |
| Axsome Therapeutics, Inc. | 1 | $74 |
| Baxter Healthcare | 1 | $20 |
| Welch Allyn | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$5,568
- Omnipod$601
- Kerendia$381
- Inspire$357
- Exogen Ultrasound Bone Healing System$132
- NUZYRA$125
- SOLIQUA 100/33$122
- MOUNJARO$122
- Arikayce$118
- Zurzuvae$113
- Livdelzi$109
- FreeStyle Libre 2$109
- Korlym$104
How this compares
$8,941 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 103 | $198,405 |
| OzempicSemaglutide | 146 | $196,759 |
| JardianceEmpagliflozin | 149 | $148,152 |
| EliquisApixaban | 69 | $62,535 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $59,686 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 55 | $46,658 |
| FarxigaDapagliflozin Propanediol | 30 | $37,550 |
| MounjaroTirzepatide | 27 | $35,240 |
| JanuviaSitagliptin Phosphate | 23 | $33,689 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $30,234 |
| TrulicityDulaglutide | 16 | $27,086 |
| VascepaIcosapent Ethyl | 31 | $17,086 |
| XareltoRivaroxaban | 17 | $16,471 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $15,459 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $12,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $94 | $79,91186 claims |
| Lilly USA, LLCMounjaro, Trulicity | $122 | $62,32643 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $122 | $9,26715 claims |
| AbbVieSynthroid | $5,636 | $1,30418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Tracy JohnsonFort Wayne$68K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.